National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Drug Information
    Posted: 08/10/2007    Updated: 08/29/2007
Page Options
Print This Page
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Related pages
Drug Information Summaries

Approval Process for New Cancer Treatments

Access to Investigational Drugs: Q & A
Doxorubicin Hydrochloride Liposome

This page contains brief information about doxorubicin hydrochloride liposome and a collection of links to more information from the National Cancer Institute (NCI), the Food and Drug Administration (FDA), and the National Library of Medicine (NLM).

US Brand Name(s):Evacet
DOXIL
Dox-SL
LipoDox
FDA Approved:Yes

Doxorubicin hydrochloride liposome is approved by the Food and Drug Administration (FDA) to treat the following types of cancer:

Doxorubicin hydrochloride liposome is also approved to be used with a drug called bortezomib to treat multiple myeloma after treatment with other chemotherapy.

Doxorubicin hydrochloride liposome is being studied in the treatment of other types of cancer.

Doxorubicin hydrochloride liposome is a form of doxorubicin hydrochloride contained inside liposomes (very tiny particles of fat). This form may work better than other forms of doxorubicin hydrochloride and have fewer side effects. Also, because its effects last longer in the body, it doesn't need to be given as often. For more information about doxorubicin hydrochloride that may apply to doxorubicin hydrochloride liposome, see the Drug Information Summary for Doxorubicin Hydrochloride.

Information from the FDA

FDA Approval for Doxorubicin Hydrochloride Liposome - Information from the FDA about the approval of this drug and the clinical trials that led to the approval.

Information from the NCI

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Clinical Trial Results: Drug Combination Shows Benefit in Relapsed/Refractory Multiple Myeloma (08/28/2007) - Important clinical trial results for this drug, background information, and how the trial was done.

Information from the NLM

MedlinePlus Information on Doxorubicin Hydrochloride - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This NLM patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Clinical Trials

Clinical Trials for Pegylated Liposomal Doxorubicin Hydrochloride - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.

Important: The drug information on this Web page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.


Back to Top


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov